heparin at therapeutic dose - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.22 [0.07, 0.67]< 10%1 study (1/-)99.6 %NAnot evaluable crucial-
death or transfer to ICU 0.70 [0.44, 1.12]< 10%1 study (1/-)93.1 %NAnot evaluable crucial-
deaths 0.22 [0.07, 0.67]< 10%1 study (1/-)99.6 %NAnot evaluable crucial-
clinical deterioration 0.69 [0.43, 1.10]< 10%1 study (1/-)93.9 %NAnot evaluable important-
death or ventilation 0.59 [0.34, 1.02]< 10%1 study (1/-)97.0 %NAnot evaluable important-
mechanical ventilation 0.70 [0.32, 1.54]< 10%1 study (1/-)81.1 %NAnot evaluable important-
ICU admission 0.79 [0.48, 1.30]< 10%1 study (1/-)82.5 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.